nach oben

Clinical Rheumatology

Erschienen in:

06.06.2020 | Original Article

Clinical effectiveness of iguratimod based on real-world data of patients with rheumatoid arthritis

verfasst von: Satoshi Mizutani, Hitoshi Kodera, Yoshiko Sato, Toshihiro Nanki, Shunji Yoshida, Hidekata Yasuoka

Erschienen in: Clinical Rheumatology | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Iguratimod (IGU) is a conventional synthetic disease-modifying drug that has been approved based on its additive effects with methotrexate (MTX) for the treatment of rheumatoid arthritis (RA). The objective of the study is to establish the effectiveness of IGU with versus IGU without MTX irrespective of whether MTX is well tolerated or not by the patients.

Methods

Disease activity scores in 177 RA patients treated using IGU were retrospectively evaluated at baseline and after 4, 12, and 24 weeks, and adverse events (AEs) were noted.

Results

IGU reduced the disease activity parameters, disease activity score (DAS)-ESR, DAS-CRP, the simplified disease activity index (SDAI), and clinical disease activity index (CDAI) in the concomitant MTX and non-MTX, female and male, and young and elderly patient groups after 24 weeks. Multivariate analysis demonstrated that IGU was more effective with concomitant MTX and in elderly and male patients. Severe AEs were observed only in the elderly group: two cases of pneumonia, 1 of pneumocystis pneumonia, 1 of heart failure, and 1 of salivary gland adenoma.

Conclusions

IGU is effective for RA, especially with concomitant MTX, and in elderly and male patients.

Key Points

• Iguratimod is effective for RA, especially with concomitant MTX, and in elderly and male patients.

• Since all serious adverse events were in the elderly group in this study, sufficient monitoring for adverse events, especially for elderly RA patients, is needed during iguratimod therapy.

Tanaka K, Aikawa Y, Kawasaki H, Asaoka K, Inaba T, Yoshida C (1992) Pharmacological studies on 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel antiinflammatory agent. 4th communication: inhibitory effect on the production of interleukin-1 and interleukin-6. Aust J Pharm 15(11):649–655

Tanaka K, Makino S, Shimotori T, Aikawa Y, Inaba T, Yoshida C (1992) Pharmacological studies of the new antiinflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4′-1-benzopyran-4-o ne. 2nd communication: effect on the arachidonic acid cascades. Arzneimittelforschung 42(7):945–950PubMed

Tanaka K, Shimotori T, Makino S, Aikawa Y, Inaba T, Yoshida C, Takano S (1992) Pharmacological studies of the new antiinflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-o ne. 1st communication: antiinflammatory, analgesic and other related properties. Arzneimittelforschung 42(7):935–944PubMed

Tanaka K, Shimotori T, Makino S, Eguchi M, Asaoka K, Kitamura R, Yoshida C (1992) Pharmacological studies on 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel antiinflammatory agent. 3rd communication: the involvement of bradykinin in its analgesic actions. Aust J Pharm 15(11):641–647

Song J, Liu H, Zhu Q, Miao Y, Wang F, Yang F, Cheng W, Xi Y, Niu X, He D, Chen G (2018) T-614 promotes Osteoblastic cell differentiation by increasing Dlx5 expression and regulating the activation of p38 and NF-kappaB. Biomed Res Int 2018:4901591–4901598. https://doi.org/10.1155/2018/4901591CrossRefPubMedPubMedCentral

Aikawa Y, Yamamoto M, Yamamoto T, Morimoto K, Tanaka K (2002) An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS- and TNF-alpha-stimulated THP-1 cells without interfering with IkappaBalpha degradation. Inflamm Res 51(4):188–194CrossRef

Kawakami A, Tsuboi M, Urayama S, Matsuoka N, Yamasaki S, Hida A, Aoyagi T, Furuichi I, Nakashima T, Migita K, Kawabe Y, Nakashima M, Origuchi T, Eguchi K (1999) Inhibitory effect of a new anti-rheumatic drug T-614 on costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells. J Lab Clin Med 133(6):566–574CrossRef

Kohno M, Aikawa Y, Tsubouchi Y, Hashiramoto A, Yamada R, Kawahito Y, Inoue K, Kusaka Y, Kondo M, Sano H (2001) Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells. J Rheumatol 28(12):2591–2596PubMed

Tanaka K, Yamamoto T, Aikawa Y, Kizawa K, Muramoto K, Matsuno H, Muraguchi A (2003) Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice. Rheumatology (Oxford) 42(11):1365–1371. https://doi.org/10.1093/rheumatology/keg381CrossRef

10.

Hara M, Abe T, Sugawara S, Mizushima Y, Hoshi K, Irimajiri S, Hashimoto H, Yoshino S, Matsui N, Nobunaga M, Nakano S (2007) Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study. Mod Rheumatol 17(1):1–9. https://doi.org/10.1007/s10165-006-0542-yCrossRefPubMed

11.

Nozaki Y, Inoue A, Kinoshita K, Funauchi M, Matsumura I (2020) Efficacy of iguratimod vs. salazosulfapyridine as the first-line csDMARD for rheumatoid arthritis. Mod Rheumatol 30(2):249–258. https://doi.org/10.1080/14397595.2019.1572267CrossRefPubMed

12.

Hara M, Ishiguro N, Katayama K, Kondo M, Sumida T, Mimori T, Soen S, Nagai K, Yamaguchi T, Yamamoto K, Iguratimod-Clinical Study G (2014) Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial. Mod Rheumatol 24(3):410–418. https://doi.org/10.3109/14397595.2013.843756CrossRefPubMed

13.

Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T (2016) 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheum 68(1):1–26. https://doi.org/10.1002/art.39480CrossRef

14.

Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JM, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poor G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960–977. https://doi.org/10.1136/annrheumdis-2016-210715CrossRefPubMed

15.

Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Yasuda S, Yamanishi Y, Kita Y, Matsubara T, Iwamoto M, Shoji T, Okada T, van der Heijde D, Miyasaka N, Koike T (2016) The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Ann Rheum Dis 75(1):75–83. https://doi.org/10.1136/annrheumdis-2015-207511CrossRefPubMed

16.

Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324CrossRef

17.

Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69(9):1580–1588. https://doi.org/10.1136/ard.2010.138461CrossRef

18.

Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, Smolen JS (2005) Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 7(4):R796–R806. https://doi.org/10.1186/ar1740CrossRefPubMedPubMedCentral

19.

Rubin DB, Schenker N (1991) Multiple imputation in health-care databases: an overview and some applications. Stat Med 10(4):585–598. https://doi.org/10.1002/sim.4780100410CrossRefPubMed

20.

Steinbrocker O, Traeger CH, Batterman RC (1949) Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc 140(8):659–662CrossRef

21.

Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP (1998) Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 102(2):322–328. https://doi.org/10.1172/JCI2676CrossRefPubMedPubMedCentral

22.

Rosenthal GJ, Germolec DR, Lamm KR, Ackermann MF, Luster MI (1987) Comparative effects on the immune system of methotrexate and trimetrexate. Int J Immunopharmacol 9(7):793–801. https://doi.org/10.1016/0192-0561(87)90075-0CrossRefPubMed

23.

Weinblatt ME, Maier AL (1989) Treatment of rheumatoid arthritis. Arthritis Care Res 2(3):S23–S32. https://doi.org/10.1002/anr.1790020311CrossRefPubMed

24.

Ishiguro N, Shibata K, Yoshimura A, Ikeuchi S, Ishii M (2019) Investigation of the predictors of the response to iguratimod therapy: a post-hoc analysis of post-marketing surveillance study. Mod Rheumatol:1–7. https://doi.org/10.1080/14397595.2019.1649110

25.

Mimori T, Harigai M, Atsumi T, Fujii T, Kuwana M, Matsuno H, Momohara S, Takei S, Tamura N, Takasaki Y, Ikeuchi S, Kushimoto S, Koike T (2017) Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan. Mod Rheumatol 27(5):755–765. https://doi.org/10.1080/14397595.2016.1265695CrossRefPubMed

Titel: Clinical effectiveness of iguratimod based on real-world data of patients with rheumatoid arthritis
verfasst von: Satoshi Mizutani
Hitoshi Kodera
Yoshiko Sato
Toshihiro Nanki
Shunji Yoshida
Hidekata Yasuoka
Publikationsdatum: 06.06.2020
Verlag: Springer International Publishing
Erschienen in: Clinical Rheumatology / Ausgabe 1/2021
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-020-05208-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Clinical effectiveness of iguratimod based on real-world data of patients with rheumatoid arthritis

Abstract

Objectives

Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Update Innere Medizin

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Objectives

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

The basics of data, big data, and machine learning in clinical practice

Precision medicine for rheumatologists: lessons from the pharmacogenomics of azathioprine

Disease course and obstetric outcomes of pregnancies in juvenile idiopathic arthritis: are there any differences among disease subtypes? A single-centre retrospective study of prospectively followed pregnancies in a dedicated pregnancy clinic

Effectiveness of platelet-rich plasma in the management of hip osteoarthritis: a systematic review and meta-analysis

Patient-provider communication about medication cost in rheumatoid arthritis

Challenges of caring for homeless patients with rheumatic and musculoskeletal disorders in Los Angeles

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Update Innere Medizin